Burning Rock Biotech Limited (BNR)

Market Cap	63.46M
Revenue (ttm)	72.30M
Net Income (ttm)	-81.94M
Shares Out	10.24M
EPS (ttm)	-7.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	676
Open	6.20
Previous Close	6.28
Day's Range	6.10 - 6.40
52-Week Range	5.72 - 24.10
Beta	0.18
Analysts	n/a
Price Target	n/a
Earnings Date	May 29, 2024

About BNR

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorect...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 786
• Stock Exchange: NASDAQ
• Ticker Symbol: BNR

Financial Performance

In 2023, BNR's revenue was 537.44 million, a decrease of -4.58% compared to the previous year's 563.24 million. Losses were -653.69 million, -32.69% less than in 2022.

Financial numbers in CNY